Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Biogen's Alzheimer's Drug Clears Toxic Protein but Misses Key Goal

STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study

STAT News1 min readAI-assisted summary
Editorial illustration for STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
Editorial illustration

Summary

Biogen recently announced results from a mid-stage clinical trial for a new Alzheimer's disease treatment called diranersen, also known as BIIB080. Unlike many well-known treatments that target a substance called amyloid, this new drug targets tau. Tau is a protein that can become toxic to brain cells, known as neurons, and is widely believed to play a major role in the memory loss and cognitive decline associated with Alzheimer's.

In the Phase 2 study, the drug successfully reduced the levels of this toxic tau protein in both the brains and spinal fluid of patients with early-stage Alzheimer's disease. Even more encouraging, the company noted that these reductions in tau were linked to a slowing of cognitive decline, suggesting the drug might help preserve memory and thinking skills.

However, the trial results were ultimately mixed because the study missed its main statistical goal. Researchers tested three different dosing levels, expecting the highest doses to produce the strongest effects. Instead, the lowest dose actually produced the best results. Because the trial failed to show a traditional dose response, where more medication predictably equals a greater effect, scientists will need to continue investigating how best to use this treatment safely and effectively.

Why it matters.

For years, the medical field has focused heavily on clearing amyloid proteins from the brains of Alzheimer's patients. Finding a successful way to target tau could open up an entirely new frontier in treating this illness. If researchers can figure out the optimal dosing for diranersen, it could eventually offer a powerful new tool to slow down the disease in its early stages, providing vital extra time for patients and their families.

Because this is only a mid-stage trial that missed its primary efficacy goal, the drug is still a long way from reaching pharmacy shelves. The unexpected finding that a lower dose works better highlights the ongoing complexities of treating brain diseases. Moving forward, researchers will need larger, late-stage trials to confirm these early cognitive benefits and ensure the drug is safe for the millions of people worldwide hoping for an Alzheimer's breakthrough.

From the source

The story in numbers.

Clinical trial stage
Phase 2
Escalating dosing regimens tested
3
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Biogen's Alzheimer's Drug Clears Toxic Protein but Misses Key Goal — Daily Strand